{"id":"NCT02667444","sponsor":"Novan, Inc.","briefTitle":"P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne","officialTitle":"A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-19","primaryCompletion":"2016-12","completion":"2016-12-09","firstPosted":"2016-01-29","resultsPosted":"2023-07-24","lastUpdate":"2023-07-24"},"enrollment":1330,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"SB204 4%","otherNames":["NVN1000"]},{"type":"DRUG","name":"Vehicle Gel","otherNames":["Placebo"]}],"arms":[{"label":"SB204 4%","type":"EXPERIMENTAL"},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.","primaryOutcome":{"measure":"Absolute Change From Baseline in Inflammatory Lesion Counts","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"SB204 4%","deltaMin":-13.1,"sd":10.27},{"arm":"Vehicle Gel","deltaMin":-10.9,"sd":10.81}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":55,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":666},"commonTop":["Nasopharyngitis","Application site pain","Application site erythema","Headache"]}}